Business Insights
Diagnostic Technologies
Diseases
Point-of-Care Testing
Research & Development
Sign In
Clinical Chemistry
Emerging Technology
Immunoassays
Molecular Diagnostics
Pathology & AI
Liquid Biopsy: Page 3
Menarini study demonstrates impact of circulating tumor cell counting on metastatic breast cancer survival
The data demonstrated that a single assessment of circulating tumor cell count by CellSearch before treatment commences may lead to increased overall survival in patients with metastatic breast cancer.
December 22, 2022
Foundation Medicine obtains FDA approval for NSCLC CDx
The blood-based test’s first group approval improves physicians’ ability to identify patients in this population for treatment with certain FDA-approved tyrosine kinase inhibitors, Foundation Medicine said.
December 21, 2022
Biodesix nabs positive coverage decisions from four private payors
The firm’s Nodify XL2 test will now be covered for enrollees of Blue Cross of North Carolina, Blue Cross Blue Shield of South Carolina, Blue Cross Blue Shield of Kansas City, and Capital District Physician’s Health Plan (CDPHP) of New York.
December 19, 2022
Agilent announces FDA approval for non-small cell lung cancer CDx
Resolution ctDx First is a liquid biopsy next-generation sequencing (NGS) assay; it has also been approved by the FDA for tumor profiling of the epidermal growth factor receptor (EGFR) gene in patients with NSCLC.
December 13, 2022
Swedish firm Elypta developing multicancer early detection test using glycosaminoglycan biomarkers
The firm this week announced the publication of research showcasing the multicancer early detection (MCED) potential of glycosaminoglycans as biomarkers of tumor metabolism.
December 7, 2022
Natera announces results for NIPT in twin-pregnancy clinical study
Using single-nucleotide polymorphism technology, the test analyzes fetal DNA obtained through a blood draw from the mother.
December 7, 2022
Personalis to collaborate with UCSF on colorectal cancer treatment study
The study will use the Next Personal assay to evaluate circulating tumor DNA (ctDNA)-based signatures associated with treatment response and adverse events in a cohort of patients with late-stage CRC who are receiving a combination therapy.
November 30, 2022
University of Tokyo researchers developing noninvasive method for early detection of childhood chronic kidney disease
By analyzing the variations in protein levels in collected urinary extracellular vesicles, the researchers believe they have discovered a first-step approach that could lead to earlier diagnosis of the disease in children.
November 9, 2022
Delfi Diagnostics to present proof-of-concept data for liver cancer detection platform
Delfi Diagnostics will present data on the efficacy of their liver cancer detection platform at the American Association for the Study of Liver Disease annual meeting.
October 28, 2022
nRichDX launches products for researchers developing liquid biopsy assays
Both products are used with nRichDX’s Revolution Sample Prep System. Researchers use the system for high-yield extraction of rare cfDNA from 1 mL to 20 mL of either plasma or urine samples.
October 24, 2022
Liquid biopsy diagnostics firm DiaCarta going public on NYSE through SPAC
The equity valuation of DiaCarta under the proposed combination is $460 million. DiaCarta is a translational genomics and molecular diagnostics firm.
October 14, 2022
Menarini Silicon Biosystems liquid biopsy tests issued CPT-PLA codes
The new CPT PLA codes are Cellsearch Circulating Multiple Myeloma Cell (CMMC) assay - 0337U and Cellsearch HER2 Circulating Tumor Cell (CTC-HER2) assay - 0338U.
October 13, 2022
Previous Page
Page 3 of 4
Next Page
